• Alias: AMG 386
    • Angiopoietin (ANG) 1 and 2 neutralizing peptibody (ligands of TIE-2 receptor), with potential antiangiogenic activity
    • Currently under investigation in phase 3 clinical trials for ovarian cancer and in phase 2 trials for glioblastoma, brain, colorectal prostate, and kidney cancers
    • Recommended dose: 175 mg/m2 (10 mg/kg) every 3 hours IV every 3 weeks (with chemotherapy
    • Half-life: 3 to 6 hours
    • Common side effects: Fatigue, peripheral edema, insomnia, upper abdominal pain, back pain, nausea/vomiting
    (Herbst et al., 2009)
    Other topics in Targeted and Immunotherapy Agents